Skip to main content

A randomized clinical trial of bermekimab treatment for clinical improvement of systemic sclerosis.

iScience

Authors: Nicky Solomonidi, Panayiotis G Vlachoyiannopoulos, Maria Pappa, Georgia Liantinioti, Sofia Ktena, Evangelos Theotikos, Antonia Elezoglou, Mihai G Netea, Evangelos J Giamarellos-Bourboulis

Increased concentrations of interleukin (IL)-1α have been recently described in tissues of patients with systemic sclerosis (SSc) suggesting that IL-1α inhibition may be a target for treatment. We conducted a double-blind, placebo-controlled study to assess the safety and efficacy of the fully humanized IL-1α blocking monoclonal antibody bermekimab in SSc. To evaluate response to treatment, we developed the score of inhibition of progression of SSc which was validated using the CRISS index and the modified CRISS index. The primary endpoint was met in 80% of bermekimab-treated patients vs. 20% of placebo-treated patients (p: 0.023). Most of efficacy was found for increase of carbon monoxide lung diffusion capacity. Production of IL-1α and TNF by circulating mononuclear cells was decreased and the absolute count of CD42/Cd62-platelets was decreased. Results suggest that bermekimab is a promising treatment for SSc.

© 2023 The Authors.

PMID: 37680472

Participating cluster members